Cargando…

Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder

BACKGROUND: Major Depressive Episodes (MDEs) may characterise many psychiatric disorders. Its pharmacotherapy is laid with unmet needs, rendering the testing of new drugs necessary. OBJECTIVE: To compare the effects of vortioxetine with those of other antidepressants (OADs) in a 1-year naturalistic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotzalidis, Georgios D., Lombardozzi, Ginevra, Matrone, Marta, Amici, Emanuela, Perrini, Filippo, Cuomo, Ilaria, De Filippis, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185761/ https://www.ncbi.nlm.nih.gov/pubmed/33441069 http://dx.doi.org/10.2174/1570159X19666210113150123

Ejemplares similares

Differential Response to Three Antidepressants in Patients with Major Depressive Episode Who Suffered Covid-19-Related Trauma
por: De Filippis, Sergio, et al.
Publicado: (2022)

P.0669 Differential response to three antidepressants in patients with major depressive episode who suffered Covid-19–related trauma
por: Lombardozzi, G., et al.
Publicado: (2021)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo, Ilaria, et al.
Publicado: (2018)

A comprehensive evaluation of adverse childhood experiences, social–emotional impairments, and neurodevelopmental disorders in cannabis-use disorder: Implications for clinical practice
por: Trovini, Giada, et al.
Publicado: (2023)

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
por: Giordano, Gloria, et al.
Publicado: (2020)

Clinical stabilisation with lacosamide of mood disorder comorbid with PTSD and fronto-temporal epilepsy
por: Cuomo, Ilaria, et al.
Publicado: (2017)

New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
por: Katona, Cornelius L, et al.
Publicado: (2014)

Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial
por: Mills, Natalie T, et al.
Publicado: (2020)

PS110. Reversal of stress-induced anhedonia by the multimodel antidepressant, vortioxetine
por: Christensen, AK, et al.
Publicado: (2016)

Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest
por: Xiong, Shihong, et al.
Publicado: (2022)

Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes
por: Di Nicola, Marco, et al.
Publicado: (2023)

A Feasibility Study of Patients with Major Depression and Substance Use Disorders: Vortioxetine as Maintenance Treatment
por: Basurte-Villamor, Ignacio, et al.
Publicado: (2022)

Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant
por: Chen, Grace, et al.
Publicado: (2013)

Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain
por: Zuena, Anna Rita, et al.
Publicado: (2018)

Inhibitory Effectiveness in Delayed-Rectifier Potassium Current Caused by Vortioxetine, Known to Be a Novel Antidepressant
por: Hsiao, Hung-Tsung, et al.
Publicado: (2022)

Cognitive impairment in post-covid-19 patients with major depressive episodes – a three-months study on the effect of vortioxetine
por: Di Nicola, M., et al.
Publicado: (2022)

Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant
por: Vento, Alessandro E., et al.
Publicado: (2021)

The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone
por: McIntyre, Roger S
Publicado: (2017)

Hippocampal PPARα Plays a Role in the Pharmacological Mechanism of Vortioxetine, a Multimodal-Acting Antidepressant
por: Wang, Yuan, et al.
Publicado: (2021)

The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
por: Cao, Bing, et al.
Publicado: (2019)

Efficacy of vortioxetine on the physical symptoms of major depressive disorder
por: Christensen, Michael Cronquist, et al.
Publicado: (2018)

In vivo electrophysiological study of the targeting of 5‐HT(3) receptor‐expressing cortical interneurons by the multimodal antidepressant, vortioxetine
por: Schweimer, Judith V., et al.
Publicado: (2022)

Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe survey
por: Raveendran, Subhara, et al.
Publicado: (2023)

Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine – a quantitative EEG study in rats
por: Leiser, S C, et al.
Publicado: (2014)

Activation of mTORC1 Signaling Cascade in Hippocampus and Medial Prefrontal Cortex Is Required for Antidepressant Actions of Vortioxetine in Mice
por: Li, Wei-Yu, et al.
Publicado: (2023)

Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
por: Alvarez, Enric, et al.
Publicado: (2014)

Effects of Vortioxetine on Sleep Architecture of Adolescents with Major Depressive Disorder
por: Mlyncekova, Zuzana, et al.
Publicado: (2023)

Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression
por: Segura-Garcia, Cristina, et al.
Publicado: (2021)

Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men
por: Wilson, Sue, et al.
Publicado: (2015)

Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
por: Chen, Grace, et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in Pediatric Patients
por: Findling, Robert L., et al.
Publicado: (2017)

Pharmacokinetics and Safety of Vortioxetine in the Chinese Population
por: Miao, Jia, et al.
Publicado: (2019)

Vortioxetine as adjunctive therapy in the treatment of schizophrenia
por: Redaelli, Sofia, et al.
Publicado: (2022)

Clinical effectiveness of vortioxetine in postcovid syndrome
por: Vikarenko, M., et al.
Publicado: (2022)

Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice in Italy: Results from the RELIEVE Study
por: De Filippis, Sergio, et al.
Publicado: (2022)

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
por: Florea, Ioana, et al.
Publicado: (2017)

Major depression with musical obsession treated with vortioxetine: a case report
por: Yoshimura, Reiji, et al.
Publicado: (2021)

Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine
por: Ye, Xiaolin, et al.
Publicado: (2021)

Effectiveness of vortioxetine in real-world clinical practice: Italian cohort results from the global RELIEVE study
por: De Filippis, S., et al.
Publicado: (2022)

Crystal structures of vortioxetine and its methanol monosolvate
por: Zhou, Xin-Bo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_3mb3lirfn04l6v3co770tmkk4o